IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.

A very small proportion of patients diagnosed with glioblastoma (GBM) survive more than 3 years. Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations define a small subgroup of GBM patients with favourable prognosis. However, it remains controversial whether long-term survivors (LTS) are found among t...

Full description

Bibliographic Details
Main Authors: Aymeric Amelot, Patricia De Cremoux, Véronique Quillien, Marc Polivka, Homa Adle-Biassette, Jacqueline Lehmann-Che, Laurence Françoise, Antoine F Carpentier, Bernard George, Emmanuel Mandonnet, Sébastien Froelich
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4497660?pdf=render

Internet

http://europepmc.org/articles/PMC4497660?pdf=render

Similar Items